MedTrace Logo

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

NCT01578421 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-08-07

No results posted yet for this study

Summary

The purpose of the study is to compare clearance and removal rates of phosphate, ß2-microglobulin (ß2-m) and leptin and albumin loss with different dialyser membranes during post-dilution online hemodiafiltration.

Conditions

  • Renal Failure Chronic Requiring Hemodialysis

Interventions

DEVICE

4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)

4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements

Sponsors & Collaborators

  • Fresenius Medical Care Deutschland GmbH

    collaborator INDUSTRY

  • Kantonsspital Aarau

    lead OTHER

Principal Investigators

  • Andreas Bock, MD · Nephrology Division, Kantonsspital Aarau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578421 on ClinicalTrials.gov